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Abstract—The reference standard MK-1064 {5''-chloro-N-((5,6-dimethoxypyridin-2-yl)methyl)-[2,2':5',3''-terpyridine]-3'-carboxamide} 
was synthesized from methyl 2-chloro-5-iodonicotinate and 5-(chloropyridin-3-yl)boronic acid in 4 steps with 33% overall chemical 
yield. The precursor desmethyl-MK-1064 {5''-chloro-N-((5-hydroxy-6-methoxypyridin-2-yl)methyl)-[2,2':5',3''-terpyridine]-3'-
carboxamide} for radiolabeling was synthesized from 2-bromopyridin-3-ol and 5''-chloro-[2,2':5',3''-terpyridine]-3'-carboxylic acid in 6 
steps with 17% overall chemical yield. The target tracer [11C]MK-1064 {5''-chloro-N-((5-[11C]methoxy-6-methoxypyridin-2-yl)methyl)-
[2,2':5',3''-terpyridine]-3'-carboxamide} was prepared by O-[11C]methylation of its corresponding precursor desmethyl-MK-1064 with 
[11C]CH3OTf under basic condition and isolated by a simplified solid-phase extraction (SPE) method in 50-60% decay corrected 
radiochemical yields based on [11C]CO2 at end of bombardment (EOB). The overall synthesis time from EOB was 23 min, the 
radiochemical purity was >99%, and the specific activity at end of synthesis (EOS) was 185-555 GBq/mol. 
Keywords: [11C]MK-1064; Orexin-2 receptor (OX2R); Positron emission tomography (PET); Sleep disorders. 
The orexin system consists of two neuropeptides: 
orexin-A (a 33 amino-acid peptide) and orexin-B (a 28 
amino-acid peptide); two G-protein coupled receptors: 
orexin-1 receptor (OX1R) and orexin-2 receptor 
(OX2R).1-4 Orexin-A activates both OX1R and OX2R 
with near equal affinity whereas orexin-B preferentially 
binds to OX2R. OX1R is selectively expressed in the 
locus coeruleus. Conversely, OX2R is expressed in the 
tuberomammillary nucleus.5 The available experimental 
evidences strongly support that OX2R plays a key role 
in motivation, arousal and sleep-wake regulation, and is 
associated with sleep disorders, irregularities in central 
vestibular motor control, feeding and gastrointestinal 
disorders and drug abuse.6 Although OX1R is thought 
to regulate sleep-wakefulness and energy homeostasis, 
particularly food intake, the therapeutic potential of 
selective antagonism of OX1R is still under evaluation.6 
Orexin receptor is an interesting therapeutic target, and 
many selective orexin receptor antagonists have been 
developed.3,4 However, the in vivo selectivity, 
distribution and involvements of OX1R and OX2R in 
the pathophysiology of orexin-related disorders are not 
fully understood.7 Biomedical imaging technique 
positron emission tomography (PET) is a useful tool for 
in vivo quantification of various biological processes.7 
OX2R has also become a promising target for molecular 
imaging of OX2R-mediated diseases and image-guided 
therapy using PET modality, and several PET 
radioligands including [11C]BBAC, [11C]BBPC, 
[11C]EMPA, [11C]CW4, and (1R,2S)-2-(3-
fluorophenyl)-N-(5-fluoropyridin-2-yl)-2-(((4-
((methoxy-11C)methyl)-2-methylpyrimidin-5-
yl)oxy)methyl)cyclopropane-1-carboxamide 
([11C]FFMMCC) have been evaluated for imaging of 
OX2R, as indicated in Figure 1.7-10 PET scans with 
[11C]BBAC and [11C]BBPC in a rhesus monkey showed 
no tracer retention and appropriate brain uptake.7 
[11C]EMPA-PET also showed poor brain uptake in both 
rats and baboon.8 [11C]CW4-PET in a baboon showed 
appropriate early brain uptake, but fast kinetics and high 
nonspecific binding.9 PET scan with [11C]FFMMCC 
showed moderate uptake in rat and monkey brains 
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under deficiency or blockade of P-glycoprotein, but this 
radioligand is not selective, and it binds to OX1R and 
OX2R with the equal affinity (Ki 1 nM for OX1R and 
OX2R).10 In view of these radioligands recently 
developed for PET imaging of OX2R, only a limited 
success is achieved. Therefore, to investigate the 
therapeutic effect and receptor occupancy of the OX2R 
antagonists and to guide the therapy, a new suitable 
radioligand for OX2R is still needed. Recently, a new 
selective OX2R antagonist (2-SORA) MK-1064 {5''-
chloro-N-((5,6-dimethoxypyridin-2-yl)methyl)-
[2,2':5',3''-terpyridine]-3'-carboxamide} has been 
discovered by Merck, it exhibited Ki (nM) and IC50 
(nM) for OX2R and OX1R, 0.5 and 18, 1584 and 1789, 
respectively, with selectivity index (SI) Ki/IC50 3168/99, 
and it is one of the most potent and selective 2-SORA 
compounds reported to date.11 Here we report the 
design, synthesis and radiolabeling of [11C]MK-1064 
{5''-chloro-N-((5-[11C]methoxy-6-methoxypyridin-2-
yl)methyl)-[2,2':5',3''-terpyridine]-3'-carboxamide} 
(Figure 1).             
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 Figure 1. PET tracers for orexin-2 receptor. 
 
The reference standard MK-1064 (5) was synthesized 
according to the reported procedures11 with 
modifications, as shown in Scheme 1. Commercially 
available starting material methyl 2-chloro-5-
iodonicotinate was undergone a Suzuki reaction with 5-
(chloropyridin-3-yl)boronic acid to obtain compound 1 
in 90% yield. Compound 1 was then converted to the 
intermediate 2 through a Stilling reaction with 2-(tri-n-
butylstannyl)pyridine in 53% yield. Compound 2 was 
hydrolyzed in methanol/water solution of KOH to yield 
the acid 3 in 98% yield, which subsequently reacted 
with (5,6-dimethoxypyridin-2-yl)methanamine (4) using 
catalysts 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and 1-
hydroxy-7-azabenzotriazole (HOAt) under basic 
condition with N,N-diisopropylethylamine (DIPEA) to 
give  MK-1064 in 70% yield. 
 
 Scheme 1. Synthesis of the reference standard MK-1064 (5). Reagents, 
conditions and yields: (i) 5-(chloropyridin-3-yl)boronic acid, PdCl2(dppf), 
Cs2CO3, DMF/water, room temperature (RT), 20 h; 90%. (ii) 2-(tri-n-
butylstannyl)pyridine, Pd(PPh3)4, CsF, CuI, DMF, 80 C, 2 h; 53%. (iii) 
KOH, MeOH, RT, 2 d; 98%. (iv) (5,6-dimethoxypyridin-2-
yl)methanamine (4), EDC, HOAt, DMF, DIPEA, RT, 15 h; 70%. 
 
Attempt to desmethlyation of MK-1064 to synthesize 
the precursor desmethyl-MK-1064 {5''-chloro-N-((5-
hydroxy-6-methoxypyridin-2-yl)methyl)-[2,2':5',3''-
terpyridine]-3'-carboxamide, 11} employing several 
methods was unsuccessful. Thus a new route for the 
synthesis of the precursor 11 was designed as depicted 
in Scheme 2. 2-Bromo-3-hydroxy pyridine was reacted 
with I2 and K2CO3 in water to afford compound 6 in 
96% yield. Compound 6 was then converted to 
compound 7 protecting phenol hydroxyl group via 
benzyl bromide in 81% yield. The bromide 7 was 
alcoholized in DMF by sodium methoxide to afford 
compound 8 in 85% yield. Compound 8 was reacted 
with CuCN at 150 C for 1.5 h to obtain compound 9 in 
73% yield. Compound 9 was undergone a 2-step 
reaction: deprotection of hydroxyl group and reduction 
of nitrile group, in one-pot under hydrogen atmosphere 
using Pd(OH)2/C as catalyst to give the key 
intermediate 10, which was converted to the precursor 
desmethyl-MK-1064 using similar procedure as 
synthesis of  MK-1064 in 35% yield. 
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 Scheme 2. Synthesis of the precursor desmethyl-MK-1064 (11). 
Reagents, conditions and yields: (i) K2CO3, H2O, I2, 5 h, RT; 96%. (ii) 
BnBr, K2CO3, CH3CN, 60 C, 12 h; 81%. (iii) MeONa, MeOH, DMF, 
100 C, 1.5 h; 85%. (iv) CuCN, DMF, 150 C, 2 h; 73 %. (v) H2 (50 psi), 
Pd(OH)2/C, MeOH, 8 h. (vi) EDC, HOAt, DMF, DIPEA, RT, 15 h; 35%. 
 
 
Synthesis of [11C]MK-1064 ([11C]5) is indicated in 
Scheme 3. The desmethyl-MK-1064 was labeled by a 
reactive [11C]methylating agent, [11C]methyl triflate 
([11C]CH3OTf)12,13 prepared from [11C]CO2, through the 
O-[11C]methylation. The labeling reaction was under 
basic conditions in acetonitrile, and the labeling mixture 
was isolated by a simplified solid-phase extraction 
(SPE) method14-17 to provide target tracers [11C]5. The 
radiochemical yields were 50-60%, decay corrected to 
end of bombardment (EOB), based on [11C]CO2.  
 
 Scheme 3. Synthesis of target tracer [11C]MK-1064 ([11C]5). Reagents, 
conditions and yields: (i) [11C]CH3OTf, CH3CN, 2 N NaOH, 80 °C, 3 
min; SPE; 50-60%.   
 
[11C]Methyl iodide ([11C]CH3I) is a most commonly 
used [11C]methylating agent,18 but [11C]CH3OTf is more 
reactive than [11C]CH3I, and thus, the radiochemical 
yield of 11C]5 was relatively high. The radiosynthesis 
including reaction, purification and formulation was 
performed in an automated self-designed multi-purpose 
11C-radiosynthesis module, allowing measurement of 
specific activity at EOB during synthesis.19-21 The 
labeling reaction was conducted using a V-vial method. 
The purification was performed by a SPE method, 
because the large polarity difference between the 
sodium salt of the phenolic hydroxyl precursor (2 N 
NaOH) and the corresponding labeled O-methylated 
ether product permitted the use of SPE technique for 
purification of the labeled product from the 
radiolabeling reaction mixture. A C-18 Plus Sep-Pak 
cartridge was used in SPE purification technique. It is 
difficult to directly elute the labeled product from a C-
18 Plus Sep-Pak to a vial using small volume of ethanol 
(1 × 1 mL or 2 × 0.5 mL), due to the back pressure in 
the C-18 Sep-Pak and dead volume in the transfer 
tubing. In order to elute most of the labeled product 
from the C-18 Sep-Pak, we need to increase the volume 
of the eluent ethanol. Thus, the formulation was 
completed by Sep-Pak trap/release and rotatory 
evaporation methods. For the radiotracer produced for 
animal study, we used ethanol (2 × 2 mL) for elution, 
and rotatory evaporation was required before 
reformulation. For the radiotracer produced for human 
study, we used ethanol (2 × 1 mL), no evaporation 
required, and a C-18 Sep-Pak was used for direct 
reformulation.22-25 We have tried to use a C-18 Light 
Sep-Pak cartridge instead of a C-18 Plus Sep-Pak 
cartridge to allow smaller volume (1 mL) of ethanol and 
to avoid laborious rotary evaporation before 
formulation. However, there is more serious back 
pressure in the Light Sep-Pak than in the Plus Sep-Pak, 
in addition, dead volume in the transfer tubing also 
affects the elution, and thus it is more difficult to 
efficiently elute the labeled product from a Light Sep-
Pak, which resulted in the low radiochemical yield. The 
reason is that our home-built fully automated module 
used many PTFE(polytetrafluoroethylene)/Silicone 
liners (septa) and Teflon tubing, and these materials 
cannot afford too high pressure gas (N2) push. The 
pressure of N2 gas introduced in our module is set at 
207 kPa (30 Psi). C-18 Light Sep-Pak cartridge works 
well in manual or semi-automated radiosynthesis in our 
lab, because we can easily introduce high pressure gas 
push during the purification and reformulation process. 
Overall synthesis time was 23 min from EOB, including 
approximately 11 min for [11C]CH3OTf production, 5 
min for O-[11C]methylation reaction, and 7 min for SPE 
purification, evaporation and reformulation. SPE 
technique is fast, efficient and convenient and works 
very well for the O-methylated ether tracer purification 
using the phenolic hydroxyl precursor for 
radiolabeling.15,26,27  
 
Specific activity is an important parameter for a brain 
radiotracer. If a reverse-phase (RP) high performance 
liquid chromatography (HPLC) is used as purification 
method, then on line determination of specific activity 
at EOB is accurate. If a SPE cartridge is used as 
purification method, then the on-the-fly technique to 
determine specific activity at EOB is not applied. The 
specific activity for the 11C-tracers produced in our PET 
chemistry facility usually ranges from 370 to 1110 
GBq/mol at EOB according to our previous works. 
The specific activity of [11C]MK-1064 was 185-555 
GBq/mol at the end of synthesis (EOS) determined by 
analytical HPLC28,29 and calculated, which are in 
agreement with the “on line” determined values. To 
achieve the highest specific activity, several procedures 
were performed.30,31 The 11C gas target we used is the 
Siemens RDS-111 Eclipse cyclotron 11C gas target. The 
technical trick to produce high specific activity 
[11C]CO2 is we will usually do 2-3 times pre-burn with 
the same beam current and short time like 10 min before 
production run. This pre-burn will warm up the 
cyclotron and eliminate significant amount of 12C 
carrier-added in the cyclotron 11C gas target. We use an 
Eckert & Ziegler Modular Lab C-11 Methyl 
Iodide/Triflate module to produce [11C]CH3OTf, 
convenient gas phase bromination of [11C]methane, and 
production of [11C]CH3OTf. This is a ‘dry’ method 
using Br2 to generate a [11C]CH3Br intermediate. 
Comparing with other ‘dry’ methods using I2 and ‘wet’ 
methods using LiAlH4 and HI, our ‘dry’ method seems 
to help minimize introduction of additional 12C carrier 
after [11C]CO2 production.13 To further help produce 
high specific activity [11C]CH3OTf, we usually do 2 
 
‘test loop’ procedures when we set up the module for 
the actual [11C]CH3OTf production run, and 1 actual 
[11C]CH3OTf production run before we do 
[11C]methylation labeling reaction. These procedures 
avoid any leak in the module to introduce additional 12C 
carrier and eliminate significant amount of original 12C 
carrier accumulated in the [11C]CH3OTf production 
system. Therefore, the specific activity of our 11C-
tracers is significantly improved.      
 
Chemical purity and radiochemical purity were 
determined by analytical HPLC.28,29 The chemical 
purity of the precursor and reference standard was 
>95%. The radiochemical purity of the target tracer was 
>99% determined by radio-HPLC through -ray (PIN 
diode) flow detector, and the chemical purity of the 
target tracer was >90% determined by reversed-phase 
HPLC through UV flow detector.  
 
The octanol-water partition coefficient (commonly 
expressed as Log P) is an important physical parameter 
directly correlated with the biological activities of a 
wide variety of organic compounds.32-35 Log P provides 
an assessment of lipophilicity that often correlates with 
a compound’s ability to penetrate the blood brain barrier 
(BBB). We obtained Log P and calculated Log P (CLog 
P) values of PET tracers for OX2R (Figure 1) from 
ChemBioDraw Ultra 14.0 (ChemOffice) as listed in 
Table 1. Log P and CLog P data of [11C]MK-1064 are 
similar to those of [11C]FFMMCC, and in the optimal 
range of LogD7.4 (2.0-3.5) reported for an optimum 
central nervous system (CNS) penetration of drug 
molecules.36 These data suggest the [11C]MK-1064 has 
appropriate lipophilicity for brain uptake.   
 
Table 1. Log P and Clog P values of PET tracers for 
OX2R. 
Compound Log P Clog P 
[11C]BBAC 4.21 4.40 
[11C]BBPC 3.79 3.06 
[11C]EMPA 2.24 3.43 
[11C]CW4 4.98 4.11 
[11C]FFMMCC 3.65 3.29 
[11C]MK-1064 3.2 3.15 
 
The experimental details and characterization data for 
compounds 1-3, 5-11 and for the tracer [11C]5 are 
given.37 
 
In summary, a simple and moderate-to-high-yield 
synthetic route to synthesize MK-1064, desmethyl-MK-
1064 and [11C]MK-1064 has been developed. An 
automated self-designed multi-purpose [11C]-
radiosynthesis module for the synthesis of [11C]MK-
1064 has been built. The target tracer was easily 
prepared by O-[11C]methylation of its corresponding 
desmethylated precursor using a reactive 
[11C]methylating agent, [11C]CH3OTf, and isolated by a 
simplified SPE purification procedure in high 
radiochemical yields, short overall synthesis time, and 
high specific radioactivities. These methods are efficient 
and convenient. It is anticipated that the approaches for 
the design, synthesis and automation of new tracer, 
authentic standard and radiolabeling precursor, and 
improvements to increase radiochemical yield and 
specific activity of the tracer described here can be 
applied with advantages to the synthesis of other 11C-
radiotracers for PET imaging. These chemistry results 
combined with the reported in vitro and in vivo 
biological data11 of MK-1064 encourage further in vivo 
biological evaluation of [11C]MK-1064 as a new 
candidate PET radioligand for imaging of OX2R in 
brain diseases.    
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mL/min; and UV (254 nm) and -ray (PIN diode) flow 
detectors. C18 Plus Sep-Pak cartridges were obtained 
from Waters Corporation (Milford, MA).  Sterile 
Millex-GS 0.22 m filter units were obtained from 
Millipore Corporation (Bedford, MA). 
(b) Methyl 5',6-dichloro-[3,3'-bipyridine]-5-
carboxylate (1): To a solution of methyl 2-chloro-5-
iodonicotinate (5.95 g, 20.0 mmol) in N,N-
dimethylformamide (DMF, 82 mL)/water (4.0 mL) 
was added 5-(chloropyridin-3-yl)boronic acid (3.20 g, 
20.3 mmol), [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II
) (Pd(dppf)Cl2, 1.46 g, 2.0 mmol) and Cs2CO3 (19.6 g, 
60.0 mmol). The reaction was stirred at RT for 24 h. 
Then the reaction mixture was partitioned between 
EtOAc and water, the organic layer was washed with 
 
water and brine, dried over MgSO4, filtered, and 
concentrated in vacuo. The residue was purified by 
trituration with MeOH followed by EtOAc/Et2O to 
give a yellow solid 1 (5.10 g, 90%). Rf = 0.70 (1:19 
MeOH/CH2Cl2), mp 135-137 C.  1H NMR (CDCl3):  
4.01 (s, 3H, OCH3), 7.89 (t, J = 2.5 Hz, 1H, Ar-H), 
8.34 (d, J = 2.5 Hz, 1H, Ar-H), 8.66 (d, J = 2.5 Hz, 
1H, Ar-H), 8.72-8.74 (m, 2H, Ar-H). MS (ESI): 283 
([M+H]+, 100%).  
(c) Methyl 5''-chloro-[2,2':5',3''-terpyridine]-3'-
carboxylate (2): To a solution of compound 1 (1.66 g, 
5.86 mmol) in DMF (30 mL) was added 2-(tri-n-
butylstannyl)pyridine (3.02 g, 8.20 mmol), CsF (2.67 
g, 17.6 mmol), CuI (223 mg, 1.17 mmol) and 
Pd(PPh3)4 (677 mg, 0.586 mmol). The mixture was 
heated to 80 C for 2 h. The reaction mixture was 
cooled, diluted with EtOAc (120 mL), and filtered 
through a pad of Celite. The filtrate was washed with 
water (2 × 50 mL) and brine (50 mL), dried over 
MgSO4, filtered and concentrated. The residue was 
purified by column chromatography on silica gel with 
eluent (5:95 to 50:50 EtOAc/hexanes) to give a white 
solid product 2 (1.01 g, 53%). Rf = 0.26 (1:2 
EtOAc/hexanes), mp 111-113 C. 1H NMR (CDCl3):  
3.84 (s, 3H, OCH3), 7.34 (ddd, J = 1.0, 5.0, 7.5 Hz, 
1H, Ar-H), 7.85 (dt, J = 2.0, 8.0 Hz, 1H, Ar-H), 7.94 
(t, J = 2.0 Hz, 1H, Ar-H), 8.12 (d, J = 2.0 Hz, 1H, Ar-
H), 8.22 (d, J = 8.0 Hz, 1H, Ar-H), 8.63 (d, J = 4.0 Hz, 
1H, Ar-H), 8.65 (d, J = 2.0 Hz, 1H, Ar-H), 8.79 (d, J = 
2.0 Hz, 1H, Ar-H), 8.94 (d, J = 2.0 Hz, 1H, Ar-H). MS 
(ESI): 326 ([M+H]+, 100%). 
(d) 5''-Chloro-[2,2':5',3''-terpyridine]-3'-carboxylic 
acid (3): To a solution of compound 2 (0.33 g, 1.0 
mmol) in methanol (30 mL)/water (3 mL) was added 
KOH (0.56 g, 10  mmol). The mixture was stirred at 
RT for 48 h. The reaction mixture was concentrated in 
vacuo. The residue was added water and HCl (1 N), 
and pH value of the mixture was adjusted to 6. The 
resulting precipitate was filtered, washed with cold 
water, and dried to afford a white solid product 3 
(0.306 g, 98%). Rf = 0.38 (1:1 MeOH/CH2Cl2), mp 
185-187 C.  1H NMR (DMSO-d6):  7.47 (t, J = 6.0 
Hz, 1H, Ar-H), 7.98 (t, J = 7.5 Hz, 1H, Ar-H), 8.11 (d, 
J = 7.5 Hz, 1H, Ar-H), 8.43 (s, 1H, Ar-H), 8.50 (s, 1H, 
Ar-H), 8.60 (d, J = 4.0 Hz, 1H, Ar-H), 8.72 (s, 1H, Ar-
H), 9.05 (s, 1H, Ar-H), 9.16 (s, 1H, Ar-H), 13.18 ( br 
s, 1H, OH). MS (ESI): 312 ([M + H]+, 56%); MS 
(ESI): 310 ([M - H]-, 14%). 
(e) 5''-Chloro-N-((5,6-dimethoxypyridin-2-yl)methyl)-
[2,2':5',3''-terpyridine]-3'-carboxamide (MK-1064, 5): 
To a solution of compound 3 (218 mg, 0.70 mmol) in 
DMF (30 mL) was added (5,6-dimethoxypyridin-2-
yl)methanamine (4, 124 mg, 0.735 mmol), EDC (268 
mg, 1.4 mmol) HOAt (237 mg, 1.4 mmol) and DIPEA 
(361 mg, 2.8 mmol). The mixture was stirred at RT for 
15 h. The reaction mixture was diluted with EtOAc 
(120 mL), washed with water (2 × 30 mL) and brine 
(30 mL), dried over MgSO4, filtered, and concentrated 
in vacuo. The residue was purified by column 
chromatography on silica gel with eluent (0:100 to 
3:97 MeOH/CH2Cl2) to give a white solid product 5 
(226 mg, 70%). Rf = 0.56 (1:9 MeOH/CH2Cl2), mp 
170-172 C. 1H NMR (DMSO-d6):  3.79 (s, 3H, 
OCH3), 3.84 (s, 3H, OCH3), 4.37 (d, J = 6.0 Hz, 2H, 
CH2), 7.16 (d, J = 8.0 Hz, 1H, Ar-H), 7.33 (d, J = 8.0 
Hz, 1H, Ar-H), 7.42 (ddd, J = 1.0, 4.5, 7.5 Hz, 1H, Ar-
H), 7.94 ( dt, J = 1.5, 7.5 Hz, 1H, Ar-H), 8.07 (d, J = 
7.5 Hz, 1H, Ar-H), 8.36 (d, J = 2.0 Hz, 1H, Ar-H), 
8.50 (t, J = 2.0 Hz, 1H, Ar-H), 8.53 (d, J = 4.0 Hz, 1H, 
Ar-H), 8.72 (d, J = 2.0 Hz, 1H, Ar-H), 8.88 (t, J = 6.0 
Hz, 1H, NH), 9.06 (d, J = 2.0 Hz, 1H, Ar-H), 9.16 (d, 
J = 2.0 Hz, 1H, Ar-H). MS (ESI): 462 ([M+H]+, 
100%). 
(f) 2-Bromo-6-iodopyridin-3-ol (6): To a solution of 2-
bromo-3-hydroxy pyridine (20.0 g, 115 mmol) in 
water (250 mL) was added K2CO3 (31.8 g, 230 mmol) 
and I2 (29.2 g, 115 mmol). The mixture was stirred at 
RT for 5 h, then cooled to 0 °C and treated with 
concentrated HCl until solids precipitated from 
solution (pH ~6). The solids were isolated by filtration 
and dried to give a brown solid 6 (33.1 g, 96%). Rf = 
0.46 (1:49 MeOH/CH2Cl2), mp 152-154 C. 1H NMR 
(DMSO-d6):  7.07 (d, J = 8.0 Hz, 1H, Ar-H), 7.59 (d, 
J = 8.0 Hz, 1H, Ar-H), 11.31 (br s, 1H, OH). MS 
(ESI): 298 ([M-H]-, 100%). 
(g) 3-(Benzyloxy)-2-bromo-6-iodopyridine (7): To a 
solution of compound 6 (12.0 g, 40.0 mmol) in 
CH3CN (150 mL) was added K2CO3 (11.6 g, 80.0 
mmol) and benzyl bromide (8.21 g, 48.0 mmol). The 
mixture was stirred at 60 C for 12 h, then cooled to 
RT, filtered, washed with CH3CN, and concentrated. 
The residue was recrystallized from EtOAc/hexanes to 
give a pale brown solid 7 (12.6 g, 81%). Rf = 0.82 (1:2 
EtOAc/hexanes), mp 82-84 C. 1H NMR (CDCl3):  
5.16 (s, 2H, CH2), 6.82 (d, J = 8.5 Hz, 1H, Ar-H), 
7.32-7.36 (m, 1H, Ar-H), 7.37-7.43 (m, 4H, Ar-H), 
7.51 (d, J = 8.5 Hz, 1H, Ar-H). MS (ESI): 390 
([M+H]+, 100%). 
(h) 3-(Benzyloxy)-6-iodo-2-methoxypyridine (8): To a 
solution of compound 7 (6.50 g, 16.6 mmol) in DMF 
(60 mL) was added MeONa (5.76 g, 26.6 mmol, 25% 
in methanol). The mixture was heated to 100 C and 
stirred for 1.5 h, then cooled to RT, and partitioned 
between EtOAc and water. The organic phase was 
washed with water and brine, dried over MgSO4, 
filtered, and concentrated. The crude product was 
purified by column chromatography on silica gel with 
eluent (5:95 to 20:80 EtOAc/hexanes) to give a white 
solid product 8 (4.81 g, 85%). Rf = 0.70 (1:5 
EtOAc/hexanes), mp 48-50 C.   1H NMR (CDCl3):  
3.99 (s, 3H, OCH3), 5.10 (s, 2H, CH2), 6.71 (d, J = 8.0 
Hz, 1H, Ar-H), 7.13 (d, J = 8.0 Hz, 1H, Ar-H), 7.31-
7.33 (m, 1H, Ar-H), 7.34-7.39 (m, 4H, Ar-H). MS 
(ESI): 342 ([M+H]+, 100%). 
(i) 5-(Benzyloxy)-6-methoxypicolinonitrile (9): To a 
solution of compound 8 (4.09 g, 12.0 mmol) in DMF 
(120 mL) was added copper cyanide (2.15 g, 24.0 
 
mmol). The mixture was heated to 150 C for 2 h, then 
cool to RT, diluted with EtOAc (250 mL), and filtered 
through a pad of Celite. The reaction mixture was 
washed with water (2 × 50 mL) and brine (50 mL), 
dried over MgSO4, filtered, and concentrated. The 
residue was purified by column chromatography on 
silica gel with eluent (5:95 to 30:70 EtOAc/hexanes) 
to give a white solid product 9 (2.10 g, 73%). Rf = 
0.28 (1:5 EtOAc/hexanes), mp 106-108 C. 1H NMR 
(DMSO-d6):  3.90 (s, 3H, OCH3), 5.22 (s, 2H, CH2), 
7.35-7.38 (m, 1H, Ar-H), 7.40-7.43 (m, 2H, Ar-H), 
7.45-7.46 (m, 2H, Ar-H), 7.50 (d, J = 8.0 Hz, 1H, Ar-
H), 7.64 (d, J = 8.0 Hz, 1H, Ar-H). MS (ESI): 242 
([M+H]+, 100%); MS (ESI): 239 ([M-H]-, 1%). 
(j) 6-(Aminomethyl)-2-methoxypyridin-3-ol (10): To a 
solution of compound 9 (360 mg, 1.5 mmol) in 
methanol (70 mL) was added Pearlman’s catalyst 
(Pd(OH)2 on carbon, 120 mg). The mixture was 
reacted under an atmosphere of hydrogen (50 psi) for 
8 h. The reaction contents were filtered through a pad 
of Celite and the filtrate was collected. The solvent 
was removed in vacuo to give a bone semi-solid crude 
product. Because of instability of the product on silica 
gel column, the product was directly used in next step 
reaction without further purification. Rf = 0.22 (1:1 
MeOH/CH2Cl2). MS (ESI): 155 ([M+H]+, 100%); MS 
(ESI): 153 ([M-H]-, 5%). 
(k) 5''-Chloro-N-((5-hydroxy-6-methoxypyridin-2-
yl)methyl)-[2,2':5',3''-terpyridine]-3'-carboxamide 
(desmethyl-MK-1064, 11): Compound 10 was reacted 
with compound 3 using the similar procedure as 
synthesis of compound 5 to give a white solid 11, 
yield 35%. Rf = 0.45 (1:19 MeOH/CH2Cl2), mp > 251 
C (decomposed). 1H NMR (DMSO-d6):  3.30 (s, 3H, 
OCH3), 4.33 (d, J = 6.0 Hz, 2H, CH2), 7.00 (d, J = 7.5 
Hz, 1H, Ar-H), 7.09 (d, J = 7.5 Hz, 1H, Ar-H), 7.41 
(dd, J = 5.0, 7.5 Hz, 1H, Ar-H), 7.92 (dt, J = 1.5, 8.0 
Hz, 1H, Ar-H), 8.06 (d, J = 8.0 Hz, 1H, Ar-H), 8.34 
(d, J = 2.0 Hz, 1H, Ar-H), 8.49 (d, J = 4.0 Hz, 1H, Ar-
H), 8.50 (t, J = 2.0 Hz, 1H, Ar-H), 8.72 (d, J = 2.0 Hz, 
1H, Ar-H), 8.82 (t, J = 6.0 Hz, 1H, NH), 9.06 (d, J = 
2.0 Hz, 1H, Ar-H), 9.14 (d, J = 2.0 Hz, 1H,Ar-H),  
9.26 (s, 1H, OH). MS (ESI): 448 ([M+H]+, 100%); 
MS (ESI): 446 ([M-H]-, 18%). HRMS (ESI): calcd for 
C23H18N5O3NaCl 470.0996 ([M+Na]+), found 
470.0986.   
(m) 5''-Chloro-N-((5-[11C]methoxy-6-methoxypyridin-
2-yl)methyl)-[2,2':5',3''-terpyridine]-3'-carboxamide 
([11C]MK-1064, [11C]5): [11C]CO2 was produced by 
the 14N(p,)11C nuclear reaction in the small volume 
(9.5 cm3) aluminum gas target provided with the 
Siemens RDS-111 Eclipse cyclotron. The target gas 
consisted of 1% oxygen in nitrogen purchased as a 
specialty gas from Praxair, Indianapolis, IN. Typical 
irradiations used for the development were 50 A 
beam current for 15 min on target.  The production run 
produced approximately 25.9 GBq of [11C]CO2 at 
EOB. Desmethyl-MK-1064 (11) (0.1-0.3 mg) was 
dissolved in CH3CN (300 L). To this solution was 
added 2 N NaOH (2 L). The mixture was transferred 
to a 5-mL small reaction vial. No-carrier-added (high 
specific activity) [11C]CH3OTf (13.9 GBq) that was 
produced by the gas-phase production method13 within 
11 min from [11C]CO2 (25.9 GBq) through [11C]CH4 
(21.8 GBq) and [11C]CH3Br (13.9 GBq) with silver 
triflate (AgOTf) column was passed into the reaction 
vial at RT until radioactivity reached a maximum (2 
min), and then the reaction vial was isolated and 
heated at 80 C for 3 min. The contents of the reaction 
vial were diluted with NaHCO3 (0.1 M, 1 mL). The 
reaction vial was connected to a C-18 Plus Sep-Pak 
cartridge. The labeled product mixture solution was 
passed onto the cartridge for SPE purification by gas 
pressure. The cartridge was washed with H2O (2  3 
mL), and the aqueous washing was discarded. The 
product was eluted from the cartridge with EtOH (2  
2 mL), and then passed onto a rotatory evaporator. 
The solvent was removed by evaporation (3 min) 
under vacuum. The final volume of ethanol after 
evaporation was ~1 mL. The labeled product [11C]5 
was reformulated with saline (10 mL), sterile-filtered 
through a sterile vented Millex-GS 0.22 m cellulose 
acetate membrane and collected into a sterile vial. 
Total radioactivity (4.7-7.1 GBq) was assayed and the 
total volume (10-11 mL) was noted for tracer dose 
dispensing. Retention times in the analytical HPLC 
system were: tR 11 = 4.13 min, tR 5 = 6.56 min, and tR 
[11C]5 = 6.64 min. 
